HK1202426A1 - Integrin antagonist conjugates for targeted delivery to cells expressing alpha-v-beta-3 -v--3 - Google Patents
Integrin antagonist conjugates for targeted delivery to cells expressing alpha-v-beta-3 -v--3Info
- Publication number
- HK1202426A1 HK1202426A1 HK15102940.0A HK15102940A HK1202426A1 HK 1202426 A1 HK1202426 A1 HK 1202426A1 HK 15102940 A HK15102940 A HK 15102940A HK 1202426 A1 HK1202426 A1 HK 1202426A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- beta
- cells expressing
- targeted delivery
- integrin antagonist
- expressing alpha
- Prior art date
Links
- 229940123038 Integrin antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/587—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with aliphatic hydrocarbon radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms, said aliphatic radicals being substituted in the alpha-position to the ring by a hetero atom, e.g. with m >= 0, Z being a singly or a doubly bound hetero atom
- C07D277/593—Z being doubly bound oxygen or doubly bound nitrogen, which nitrogen is part of a possibly substituted oximino radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the nitrogen atom of at least one of the carboxamide groups further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/20—Esters of monothiocarboxylic acids
- C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
- C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
- C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261591299P | 2012-01-27 | 2012-01-27 | |
US201261678669P | 2012-08-02 | 2012-08-02 | |
PCT/EP2013/051082 WO2013110578A1 (fr) | 2012-01-27 | 2013-01-22 | Conjugués d'antagoniste de l'intégrine pour une administration ciblée à des cellules exprimant l'alpha-v-bêta-3 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1202426A1 true HK1202426A1 (en) | 2015-10-02 |
Family
ID=47628132
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15102940.0A HK1202426A1 (en) | 2012-01-27 | 2015-03-23 | Integrin antagonist conjugates for targeted delivery to cells expressing alpha-v-beta-3 -v--3 |
Country Status (12)
Country | Link |
---|---|
US (1) | US9586916B2 (fr) |
EP (1) | EP2806899B1 (fr) |
JP (1) | JP6316209B2 (fr) |
KR (1) | KR20150009952A (fr) |
CN (1) | CN104144706B (fr) |
BR (1) | BR112014016736A8 (fr) |
CA (1) | CA2856619A1 (fr) |
ES (1) | ES2605939T3 (fr) |
HK (1) | HK1202426A1 (fr) |
MX (1) | MX2014008373A (fr) |
RU (1) | RU2623441C2 (fr) |
WO (1) | WO2013110578A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9650363B2 (en) * | 2012-01-27 | 2017-05-16 | Hoffmann-La Roche Inc. | Integrin antagonist conjugates for targeted delivery to cells expressing LFA-1 |
US9447035B2 (en) * | 2012-01-27 | 2016-09-20 | Hoffmann-La Roche Inc. | Integrin antagonist conjugates for targeted delivery to cells expressing VLA-4 |
RU2624731C2 (ru) * | 2012-01-27 | 2017-07-06 | Ф. Хоффманн-Ля Рош Аг | Конъюгаты антагонистов интегрина для нацеленной доставки к клеткам, экспрессирующим vla-4 |
WO2015021092A1 (fr) * | 2013-08-07 | 2015-02-12 | Arrowhead Research Corporation | Polyconjugués pour l'administration de déclencheurs d'arni à des cellules tumorales in vivo |
ES2884107T3 (es) * | 2016-11-11 | 2021-12-10 | Zealand Pharma As | Multímeros de péptidos cíclicos con diana en la integrina alfa-4 beta-7 |
CN110283223B (zh) * | 2018-03-19 | 2022-01-04 | 广州市锐博生物科技有限公司 | 一种阳离子脂质分子及其在核酸递送中的应用 |
SI3784269T1 (sl) * | 2018-04-27 | 2024-08-30 | Arrowhead Pharmaceuticals, Inc., | Integrinski ciljni ligandi in njihova uporaba |
WO2020056064A1 (fr) * | 2018-09-11 | 2020-03-19 | Stanley Satz | Thérapie par radionucléides ciblée antitumorale et imagerie moléculaire de cancers her2 + et d'autres néoplasmes, et médicament de précision |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000508319A (ja) * | 1996-04-10 | 2000-07-04 | メルク エンド カンパニー インコーポレーテッド | αvβ3拮抗薬 |
RU2001132141A (ru) * | 1999-04-28 | 2004-03-20 | БАСФ Акциенгезельшафт (DE) | Антагонисты интегриновых рецепторов |
ITRM20040241A1 (it) * | 2004-05-13 | 2004-08-13 | Ist Naz Stud Cura Dei Tumori | Camptotecine coniugate in posizione 20 con antagonisti delle integrine. |
US7300940B2 (en) * | 2004-08-04 | 2007-11-27 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Integrin α-v β-3 antagonists for use in imaging and therapy |
ES2539126T3 (es) * | 2004-12-09 | 2015-06-26 | Janssen Biotech, Inc. | Inmunoconjugados anti integrina, métodos para su producción y su uso |
US8686044B2 (en) | 2008-08-13 | 2014-04-01 | Mitsui Chemicals Agro, Inc. | Amide derivative, pest control agent containing the amide derivative, and use of the amide derivative |
PL2350043T3 (pl) | 2008-10-09 | 2014-09-30 | Tekmira Pharmaceuticals Corp | Ulepszone aminolipidy i sposoby dostarczania kwasów nukleinowych |
-
2013
- 2013-01-22 MX MX2014008373A patent/MX2014008373A/es unknown
- 2013-01-22 CA CA2856619A patent/CA2856619A1/fr not_active Abandoned
- 2013-01-22 ES ES13701748.9T patent/ES2605939T3/es active Active
- 2013-01-22 WO PCT/EP2013/051082 patent/WO2013110578A1/fr active Application Filing
- 2013-01-22 CN CN201380006790.8A patent/CN104144706B/zh active Active
- 2013-01-22 BR BR112014016736A patent/BR112014016736A8/pt active Search and Examination
- 2013-01-22 RU RU2014132565A patent/RU2623441C2/ru not_active IP Right Cessation
- 2013-01-22 KR KR1020147023904A patent/KR20150009952A/ko not_active Application Discontinuation
- 2013-01-22 JP JP2014553678A patent/JP6316209B2/ja not_active Expired - Fee Related
- 2013-01-22 EP EP13701748.9A patent/EP2806899B1/fr active Active
- 2013-01-22 US US14/374,680 patent/US9586916B2/en active Active
-
2015
- 2015-03-23 HK HK15102940.0A patent/HK1202426A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2856619A1 (fr) | 2013-08-01 |
ES2605939T3 (es) | 2017-03-17 |
JP2015506946A (ja) | 2015-03-05 |
CN104144706A (zh) | 2014-11-12 |
RU2014132565A (ru) | 2016-03-20 |
US9586916B2 (en) | 2017-03-07 |
US20150038523A1 (en) | 2015-02-05 |
JP6316209B2 (ja) | 2018-04-25 |
BR112014016736A8 (pt) | 2017-07-04 |
EP2806899B1 (fr) | 2016-10-19 |
WO2013110578A1 (fr) | 2013-08-01 |
KR20150009952A (ko) | 2015-01-27 |
RU2623441C2 (ru) | 2017-06-26 |
EP2806899A1 (fr) | 2014-12-03 |
MX2014008373A (es) | 2014-09-26 |
CN104144706B (zh) | 2017-03-29 |
BR112014016736A2 (pt) | 2017-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20182129T1 (hr) | Konjugati protutijelo - pirolobenzodiazepin | |
HK1207388A1 (en) | Self-stabilizing linker conjugates | |
EP2723393A4 (fr) | Conjugués de médicaments à ciblage extracellulaire | |
HK1211623A1 (en) | Cell lines | |
IL238448B (en) | Oligonucleotide conjugates | |
HK1196257A1 (zh) | -抗體結合物 | |
IL229695B (en) | Protein-polymer-drug conjugates | |
HUE039329T2 (hu) | Pirrolobenzodiazepin-antitest konjugátumok | |
IL228404A0 (en) | Antibody-drug captures | |
HK1202426A1 (en) | Integrin antagonist conjugates for targeted delivery to cells expressing alpha-v-beta-3 -v--3 | |
EP2698206A4 (fr) | Broyeur conique | |
EP2876715A4 (fr) | Pile à combustible | |
EP2911230A4 (fr) | Cellule | |
EP2683737A4 (fr) | Conjugués de médicament ciblés extracellulaires | |
EP2831949A4 (fr) | Cellules à sodium-oxygène | |
EP2899786A4 (fr) | Pile à combustible | |
IL239484A0 (en) | Materials for omitting enterprise-tumor cells | |
EP2698205A4 (fr) | Broyeur conique | |
EP2919308A4 (fr) | Pile à combustible du type à polyélectrolyte | |
HK1201472A1 (en) | Integrin antagonist conjugates for targeted delivery to cells expressing vla-4 vla-4 | |
EP2830130A4 (fr) | Pile à combustible | |
GB201220864D0 (en) | Improvements to agoods storage area | |
HK1202425A1 (en) | Integrin antagonist conjugates for targeted delivery to cells expressing lfa-1 lfa-1 | |
EP2882020A4 (fr) | Pile à combustible | |
GB2500031B (en) | Fuel cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20240122 |